Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.

Literature DB >> 14506053

Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.

Verica Risovic¹, Michael Boyd, Eugene Choo, Kishor M Wasan.

Abstract

The purpose of this study was to determine the effects of various lipid and mixed-micelle formulations on the oral absorption and renal toxicity of amphotericin B (AMB) in rats. The maximum concentration of AMB in plasma and the area under the concentration-time curve for 0 to 24 h for AMB were elevated in rats administered triglyceride (TG)-rich AMB formulations in comparison to those in rats given (i) AMB preformulated as a micelle containing sodium deoxycholate with sodium phosphate as a buffer (DOC-AMB), (ii) an AMB-lipid complex suspension, or (iii) AMB solubilized in methanol. Furthermore, our findings suggest that AMB incorporated into TG-based oral formulations has less renal toxicity than DOC-AMB.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2003 PMID： 14506053 PMCID： PMC201114 DOI： 10.1128/AAC.47.10.3339-3342.2003

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

22 in total

1. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.

Authors: L C Souza; A Campa
Journal: J Antimicrob Chemother Date: 1999-07 Impact factor: 5.790

2. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Authors: René Holm; Christopher J H Porter; Anette Müllertz; Henning G Kristensen; William N Charman
Journal: Pharm Res Date: 2002-09 Impact factor: 4.200

3. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats.

Authors: K M Wasan; K Vadiei; G Lopez-Berestein; D R Luke
Journal: J Infect Dis Date: 1990-03 Impact factor: 5.226

4. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion.

Authors: L C Souza; R C Maranhão; S Schreier; A Campa
Journal: J Antimicrob Chemother Date: 1993-07 Impact factor: 5.790

Review 5. Current role of therapy with amphotericin B.

Authors: R D Meyer
Journal: Clin Infect Dis Date: 1992-03 Impact factor: 9.079

6. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity.

Authors: E Sócrates T Egito; Ivonete B Araújo; Bolivar P G L Damasceno; James C Price
Journal: J Pharm Sci Date: 2002-11 Impact factor: 3.534

Review 7. The role of lymphatic transport in enhancing oral protein and peptide drug delivery.

Authors: Kishor M Wasan
Journal: Drug Dev Ind Pharm Date: 2002-10 Impact factor: 3.225

8. Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study.

Authors: L C Souza; P H Saldiva; A Campa
Journal: Exp Toxicol Pathol Date: 2000-05

9. In vivo model for ciclosporin intestinal absorption in lipid vehicles.

Authors: J P Reymond; H Sucker; J Vonderscher
Journal: Pharm Res Date: 1988-10 Impact factor: 4.200

Review 10. Amphotericin B and its delivery by liposomal and lipid formulations.

Authors: C Gates; R J Pinney
Journal: J Clin Pharm Ther Date: 1993-06 Impact factor: 2.512

14 in total

1. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.

Authors: Faisal Usman; Jongdee Nopparat; Ibrahim Javed; Teerapol Srichana
Journal: Drug Deliv Transl Res Date: 2020-02 Impact factor: 4.617

2. Enhanced oral bioavailability of griseofulvin via niosomes.

Authors: Pratap S Jadon; Virendra Gajbhiye; Rajesh S Jadon; Kavita R Gajbhiye; Narayanan Ganesh
Journal: AAPS PharmSciTech Date: 2009-10-24 Impact factor: 3.246

Review 3. Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors: Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal: Expert Opin Drug Metab Toxicol Date: 2019-06-17 Impact factor: 4.481

4. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles.

Authors: Jiang-nan Yu; Yuan Zhu; Li Wang; Min Peng; Shan-shan Tong; Xia Cao; Hui Qiu; Xi-ming Xu
Journal: Acta Pharmacol Sin Date: 2010-06 Impact factor: 6.150

5. A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats.

Authors: Hilda Amekyeh; Nashiru Billa; Kah-Hay Yuen; Sherlyn Lim Sheau Chin
Journal: AAPS PharmSciTech Date: 2015-01-15 Impact factor: 3.246

6. Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability.

Authors: Zhiwen Yang; Yinhe Tan; Meiwan Chen; Linghui Dian; Ziyun Shan; Xinsheng Peng; Chuanbin Wu
Journal: AAPS PharmSciTech Date: 2012-10-23 Impact factor: 3.246

7. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone.

Authors: J L Italia; M M Yahya; D Singh; M N V Ravi Kumar
Journal: Pharm Res Date: 2009-02-13 Impact factor: 4.200